Wilson Sonsini Reps Fluidigm In $207M DVS Sciences Deal

Law360, New York (January 29, 2014, 6:38 PM EST) -- Biotech tools company Fluidigm Corp. has signed a deal to buy DVS Sciences Inc. for $207.5 million, strengthening its portfolio in single-cell analysis technology, the company said Wednesday.

Fluidigm said it has come to a definitive agreement to acquire DVS in a cash and stock deal, creating a company with a comprehensive portfolio of biotechnologies. Fluidigm is funding the cash portion of the acquisition with proceeds from a proposed convertible notes offering, the company said. The deal is expected to close next month, after which DVS...
To view the full article, register now.